Gregory S. Curhan

Greg Curhan has been the acting CFO of Curevo Vaccine since 2020. He has over 35 years of operational, financial, capital markets, and strategic advisory experience in various sectors including Investment Banking, Medical Device/Life Sciences, Internet, Clean Technology, and Investment/Wealth Management. Greg has been a Partner at FLG Partners since 2020. As CFO, Greg has managed Finance, Legal, HR, and Investor Relations functions for Public and Private companies. He has raised equity and debt capital for both private and public companies, completed numerous successful IPOs, and executed M&A transactions both acquiring and divesting companies. He has also served in CEO, President, and Board of Director capacities. In July 2020, Greg was appointed to the Advisory Board at Specific Diagnostics as the company prepares to launch its Reveal rapid susceptibility testing system in Europe.

Greg founded and was President of an investment bank (Merriman Curhan Ford) growing it from a pre-revenue startup to 250 employees, $90 million in revenue, profitability, and a Nasdaq listing within 7 years. The investment bank raised over $5 billion dollars for corporate clients (both public and private) during that period in IPOs, Public offerings, PIPE financings, and Private Placements, while also executing successful M&A engagements in various Technology, Biotech, Medical Technology, and Consumer sectors.